Optimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractBacteria-mediated tumor therapy using Salmonella enterica serovar Typhimurium is a therapeutic option with great potential. Numerous studies explored the potential of Salmonella Typhimurium for therapeutic applications, however reconciling safety with vectorial efficacy remains a major issue. Recently we have described a conditionally attenuated Salmonella vector that is based on genetic lipopolysaccharide modification. This vector combines strong attenuation with appropriate anti-tumor properties by targeting various cancerous tissues in vivo. Therefore, it was promoted as an anti-tumor agent. In this addendum, we summarize these findings and demonstrate additional optimization steps that may further improve the therapeutic efficacy of our vector strain.
CitationOptimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy. 2016, 7 (2):171-7 Gut Microbes
AffiliationHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
PubMed Central IDPMC4856459
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy.
- Authors: Frahm M, Felgner S, Kocijancic D, Rohde M, Hensel M, Curtiss R 3rd, Erhardt M, Weiss S
- Issue date: 2015 Apr 14
- Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.
- Authors: Fu W, Chu L, Han X, Liu X, Ren D
- Issue date: 2008 Jun
- Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
- Authors: Gentschev I, Fensterle J, Schmidt A, Potapenko T, Troppmair J, Goebel W, Rapp UR
- Issue date: 2005 Feb 9
- Refined live attenuated Salmonella enterica serovar Typhimurium and Enteritidis vaccines mediate homologous and heterologous serogroup protection in mice.
- Authors: Tennant SM, Schmidlein P, Simon R, Pasetti MF, Galen JE, Levine MM
- Issue date: 2015 Dec
- Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
- Authors: Guo Y, Chen Y, Liu X, Min JJ, Tan W, Zheng JH
- Issue date: 2020 Jan 28